Neutralisation of α-neurotoxins using human recombinant igg antibodies

Andreas Hougaard Laustsen (Inventor), Line Ledsgaard Jensen (Inventor), John McCafferty (Inventor), Aneesh Karatt-Vellatt (Inventor), Bruno Lomonte (Inventor), José Maria Gutiérrez (Inventor)

Research output: Patent

20 Downloads (Pure)


In the field of recombinant antivenoms, a major hurdle to the development of antigen-binding proteins enabling sufficient toxin neutralization is the identification of antigen-binding proteins with both high affinity and broad cross-reactivity against venom toxins. Traditional antibody development approaches used failed to isolate antigen-binding proteins against venom toxins with such properties. The present disclosure describes the development of high-affinity human antibodies that show broadly-neutralizing effects against neurotoxic elapid snake venom in vitro and in vivo. The invention relates to antigen-binding proteins capable of binding to, blocking, or neutralizing two or more different α-neurotoxins. The disclosure also provides pharmaceutical compositions, kit of parts and kits for the treatment and diagnosis of snake envenomation.

Original languageEnglish
IPCC07K 16/ 18 A I
Patent numberWO2023209212
Filing date29/04/2022
Country/TerritoryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date29/04/2022
Priority numberEP20220170880
Publication statusPublished - 2 Nov 2023


Dive into the research topics of 'Neutralisation of α-neurotoxins using human recombinant igg antibodies'. Together they form a unique fingerprint.

Cite this